Search results (49)
« Back to Latest newsOxford Bundibugyo ebolavirus vaccine candidate receives CEPI backing
1 June 2026
The Coalition for Epidemic Preparedness Innovations (CEPI) has announced today that it will urgently accelerate the development of three investigational vaccines targeting the Bundibugyo ebolavirus that has caused a rapidly spreading epidemic in the Democratic Republic of the Congo (DRC) and neighbouring Uganda, including one being developed by the Oxford Vaccine Group at the University of Oxford.
University of Oxford launches new public awareness campaign for Neurodevelopmental Disorders
28 May 2026
The Department of Paediatrics at the University of Oxford today announces the launch of Genes, Brains, and Breakthroughs, a new educational campaign designed to raise public awareness and understanding of neurodevelopmental disorders through a series of accessible, family-informed video resources.
Statement on vaccine efforts relating to the Bundibugyo Ebolavirus outbreak in the DRC
22 May 2026
In response to the current Bundibugyo Ebolavirus outbreak in the Democratic Republic of the Congo, the Oxford Vaccine Group (OVG) is working urgently with Oxford’s own Clinical BioManufacturing Facility and the Serum Institute of India Pvt. Ltd. (SIIPL), to rapidly produce and scale doses of our ChAdOx-based monovalent Bundibugyo Ebolavirus candidate vaccine, ChAdOx1 BDBV.
Antiretroviral therapy blocks rapid HIV-driven evolution of humans Oxford-led study finds
28 April 2026
A new study led by researchers at the University of Oxford demonstrates that the huge success of effective antiretroviral therapy (ART) against HIV could have altered the course of human evolution.
Magdalen College lit up for Rare Disease Day
2 March 2026
Magdalen College Chapel was lit up in the colours of Rare Disease Day last week, as part of the global Chain of Lights initiative.
Global Consortium Launched to Develop Next-Generation Malaria Vaccine
8 December 2025
A new international consortium has been established to advance the development of a next-generation malaria vaccine, that aims to extend the protection against malaria and help lead to future efforts to eliminate it by targeting multiple stages of the parasite’s life-cycle.
Oxford Cancer Announces 2025 CRIS Cancer Clinical Career Fellows
20 October 2025
Dr Rebecca Ling, a DPhil student in our Childhood Leukaemia Research Group, has been made one of two CRIS Cancer Postdoctoral Clinical Fellows for 2025.
Major investment puts UK universities at the forefront of groundbreaking lymph node research
14 October 2025
Three UK universities have been granted over £1.7m by the Medical Research Council (MRC) to establish a network of lymph node research centres across the UK. The novel LEGACY IIII Network (Lymph nodE single cell Genomics AnCestrY immunity, infection, inflammation and immunisation) will be co-led by the Universities of Oxford, Cardiff and Newcastle and will establish ten specialist lymph node research centres across the country.
The Kaiya Foundation to fund Leukaemia Research at University of Oxford
1 September 2025
The Kaiya Foundation has awarded one of its first major research grants, which will fund pioneering research into the fundamental cause of a high-risk leukaemia. The grant is being made to Dr Emily Neil and Professor Anindita Roy from the Childhood Leukaemia Research Group, based at the University of Oxford, in the hope that their discoveries will transform treatment approaches for sufferers through personalised medicine.
Professor Simon Draper elected Fellow of the Academy of Medical Sciences
22 May 2025
Simon Draper, Professor of Vaccinology and Translational Medicine at the Department of Paediatrics and Kavli Institute for Nanoscience Discovery, has been elected as a Fellow to the Academy of Medical Sciences, it has been announced today.
New MenB Vaccine Shows Promise in Early-Stage Trial Results
19 May 2025
The outcome of a trial published in Science Translational Medicine, shows encouraging results for a new vaccine targeting group B meningococcus (MenB), a significant cause of meningococcal disease worldwide, and establishes proof-of-concept in humans that a gene-based vaccine platform can induce protective antibody responses against bacteria.
Spotlight on Magdalen College Chapel for Rare Disease Day
28 February 2025
The chapel facade of Magdalen College was lit up ahead of the commemoration of Rare Disease Day (RDD) which was celebrated on Friday 28th February 2025. The celebration is held on 29th February in a leap year as it is the rarest day in the year.
Oxford and partners lead on two new MRC Centres to create cutting-edge gene therapies
11 December 2024
Oxford University researchers are to lead and co-lead on two MRC research centres, which are being launched to develop new advanced treatments for currently untreatable diseases.
Dr. Nicky Whiffin awarded Balfour Lecture 2025
22 November 2024
Nicky Whiffin, Associate Professor and Sir Henry Dale Fellow at the University of Oxford’s Big Data Institute and Centre for Human Genetics, has been awarded the 2025 Balfour Lecture by the Genetics Society.
New research identifies autoimmunity against a key anti-inflammatory regulator in inflammatory bowel disease
4 August 2024
- Clinical Trials
- Department
- Gastroenterology
- Immunology
- Publication
- Research
- Research Methods
- University
A ground-breaking study, published by the New England Journal of Medicine, has identified a new disease-inducing mechanism for inflammatory bowel disease (IBD) in which the immune system attacks its own regulatory function.
New research assesses the function of a major genetic cause of neurodevelopmental disorders
22 May 2024
New research, published today, has defined the functional impacts of hundreds of variants in a gene that is a major cause of neurodevelopmental disorders.
Professor Teresa Lambe OBE elected to the Fellowship of the Academy of Medical Sciences
21 May 2024
Professor Teresa Lambe OBE, Calleva Head of Immunology at the Oxford Vaccine Group, and Principal Investigator at the Pandemic Sciences Institute, has been elected a Fellow of the Academy of Medical Sciences, one of the most prestigious awards in the field.
Professor Sir Andrew Pollard elected to the Fellowship of the Royal Society
16 May 2024
Professor Sir Andrew Pollard, Director of the Oxford Vaccine Group at the Department of Paediatrics, and Ashall Professor of Infection and Immunity has today been elected a Fellow of the Royal Society.
How the Information Security Office and the National Cyber Security Centre keeps Oxford's research secure post-pandemic
2 May 2024
Oxford University's Information Security Office (InfoSec) invited the NCSC to Oxford to thank them for the work they did that kept Oxford’s vaccine research secure.
Oxford hosts Belgian vaccine experts
28 March 2024
Researchers from Oxford Vaccine Group and the Pandemic Sciences Institute welcomed a delegation of vaccine researchers from Belgium to further UK-Belgian collaboration on vaccine development and manufacture.